Cd11b Cd115 F4/80

CD11b, CD115, and F4/80 provide complementary information because each marks a different feature of the myeloid-cell phenotype. CD11b identifies an integrin associated with myeloid cells, CD115 reflects the receptor for macrophage colony-stimulating factor, and F4/80 contributes macrophage-associated information. Examining their combined expression helps distinguish cell populations more effectively than relying on one antigen alone.

CD11b alone mainly indicates association with myeloid cells, so it provides less characterization than the full panel. Adding CD115 supplies information linked to the macrophage colony-stimulating factor receptor, while F4/80 adds a macrophage-associated signal. Their combined readout supports more nuanced separation of monocyte- and macrophage-related populations.

Differences in CD11b, CD115, and F4/80 expression can be used to examine progression within myeloid populations rather than simply count all marker-positive cells. The panel supports maturation analysis by comparing marker patterns and can reveal how the representation of these populations differs across tissues. Interpretation remains tied to the measured expression profile in each sample.

In a flow-cytometry experiment, cells are exposed to fluorescently labeled antibodies directed against CD11b, CD115, and F4/80. The antibodies bind their corresponding surface markers, and the instrument detects the resulting fluorescence for each cell. Researchers can then examine marker-positive populations and compare their abundance or expression patterns across samples.

During infection studies, this panel can track changes in innate immune populations after pathogen exposure or treatment. Observed shifts can be evaluated in relation to inflammatory recruitment and macrophage differentiation. This provides a way to connect changes in myeloid-cell composition with the experimental infection or intervention and to assess how treatment affects these immune populations.

The panel is useful when the question concerns where myeloid populations are found and how their abundance changes between experimental conditions. Researchers can compare tissue samples, infection states, or treatment groups using the same marker framework, then assess differences in population representation and marker expression. This supports analysis of tissue distribution alongside broader immune changes.